Kjetil Taskén

[vc_empty_space height=”80px”][vc_row][vc_column][vc_row_inner css=”.vc_custom_1476862185021{padding-bottom: 30px !important;}”][vc_column_inner width=”2/3″][vc_column_text css=”.vc_custom_1477985450741{margin-bottom: 20px !important;}”]

Kjetil Taskén

Centre for Molecular Medicine Norway
[/vc_column_text][labora_vc_staff_info][/vc_column_inner][/vc_row_inner] [vc_row_inner css=”.vc_custom_1476862170589{padding-bottom: 30px !important;}”][vc_column_inner][vc_column_text]

Area of Expertise

MD, PhD, Professor of Medicine, will take up the position of Head of Institute for Cancer Research at Oslo University Hospital in 2018.

He is the also the director of the Centre for Molecular Medicine Norway (NCMM) at the University of Oslo, part of the Nordic EMBL Partnership. He was also the director of the Biotechnology Centre of Oslo from 2003-2016. He is the director for Norway of the ESFRI infrastructures EU-OPENSCREEN (academic chemical biology and screening) and EATRIS (translational medicine) and in charge of the corresponding national infrastructures.

Taskén has been a co-founder, board member and VP R&D of three SMEs and has been or is on the board of a number of other SMEs in the biotech sector in the field of drug development. He is also involved with several commercialisation projects. He received the Anders Jahre Medical Prize for Young Scientists 2002 (Nordic award), and won the King Olav V’s Prize for Cancer Research 2016.

He is author of more than 250 scientific publications and inventor of more than 15 patents in the areas of hormonal regulation and compartmentalised cellular signalling, immunology and cancer. He is interested in translational research and drug development in the areas of immunomodulation in treatment of HIV infection and cancer, and in heart physiology and metabolism. Taskén is the PI of more than 15 current grants. He has been cited some 10,000 times, with an H-index of 53.

[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_column][/vc_row]